首页> 外文OA文献 >Expression of Urokinase-Type Plasminogen Activator (uPA), its Receptor (uPAR), and Inhibitor (PAI-1) in Human Breast Carcinomas and Their Clinical Relevance

【2h】

Expression of Urokinase-Type Plasminogen Activator (uPA), its Receptor (uPAR), and Inhibitor (PAI-1) in Human Breast Carcinomas and Their Clinical Relevance

机译：尿激酶型纤溶酶原激活剂（UPA），其受体（UPAR）和抑制剂（PAI-1）在人乳腺癌中的表达及其临床相关性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Sarah A. Andres; Angelena B. Edwards; James L. Wittliff;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Expression of Urokinase-Type Plasminogen Activator (uPA), its Receptor (uPAR), and Inhibitor (PAI-1) in Human Breast Carcinomas and Their Clinical Relevance [J] . AndresS.A., EdwardsA.B., WittliffJ.L. Journal of clinical laboratory analysis. . 2012,第2期

机译：尿激酶型纤溶酶原激活物（uPA），其受体（uPAR）和抑制剂（PAI-1）在人乳腺癌中的表达及其临床意义
2. Expression of Urokinase‐Type Plasminogen Activator (uPA), its Receptor (uPAR), and Inhibitor (PAI‐1) in Human Breast Carcinomas and Their Clinical Relevance [J] . Sarah A. Andres, Angelena B. Edwards, James L. Wittliff Journal of clinical laboratory analysis. . 2012,第2期

机译：尿激酶型纤溶酶原激活物（uPA），其受体（uPAR）和抑制剂（PAI-1）在人乳腺癌中的表达及其临床意义
3. Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma - a 7.5-year follow-up study. [J] . Jelisavac Cosic S, Sirotkovic Skerlev M, Kulic A, Tumori. . 2011,第4期

机译：尿激酶型纤溶酶原激活物（uPA）和纤溶酶原激活物抑制剂（PAI-1）在原发性浸润性导管癌患者中的预后意义-一项为期7.5年的随访研究。
4. Inhibition of the Tumor-Associated Urokinase-Type Plasminogen Activation System: Effects of High-Level Synthesis of Soluble Urokinase Receptor in Ovarian and Breast Cancer Cells In Vitro and In Vivo [C] . Viktor Magdolen International Meeting on Molecular Staging on Cancer . 2003

机译：抑制肿瘤相关的尿激酶型纤溶酶原激活系统：高水平合成在体外和体内卵巢癌细胞中可溶性尿激酶受体的影响
5. Animal models of atherosclerosis: Overexpression of plasminogen activator inhibitor type 1 (PAI-1) and tissue factor in the rat carotid artery. [D] . Hasenstab, David Reinier. 1998

机译：动脉粥样硬化的动物模型：大鼠颈动脉中纤溶酶原激活物抑制剂1型（PAI-1）和组织因子的过表达。
6. Expression of Urokinase‐Type Plasminogen Activator (uPA) its Receptor (uPAR) and Inhibitor (PAI‐1) in Human Breast Carcinomas and Their Clinical Relevance [O] . Sarah A. Andres, Angelena B. Edwards, James L. Wittliff 2012

机译：尿激酶型纤溶酶原激活剂（uPA）其受体（uPAR）和抑制剂（PAI-1）在人乳腺癌中的表达及其临床意义
7. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. [O] . Bouchet, C., Spyratos, F., Martin, P. M., 1994

机译：尿激酶型纤溶酶原激活物（uPA）和纤溶酶原激活物抑制剂PAI-1和PAI-2在乳腺癌中的预后价值。

Expression of Urokinase-Type Plasminogen Activator (uPA), its Receptor (uPAR), and Inhibitor (PAI-1) in Human Breast Carcinomas and Their Clinical Relevance

著录项

引文网络

相似文献

相关主题

期刊订阅